Roche, a research-intensive healthcare company, announced that data from 138 abstracts will be presented at this year’s European Cancer Congress (ECC) from 25–29 September in Vienna, Austria.
Results will be presented from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder and skin cancer (alectinib, atezolizumab and cobimetinib, which recently received its first approval in Switzerland where it is marketed as Cotellic). Building on its large portfolio of approved cancer medicines, these regulatory discussions represent significant progress for Roche’s pipeline in the fields of cancer immunotherapy and targeted medicines.
"With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer," said Sandra Horning, M.D., Roche’s chief medical officer and head of global product development.
"At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancers."
In addition to data for alectinib, atezolizumab and cobimetinib, results will be presented across multiple tumour types from Roche’s cancer immunotherapy and targeted medicines pipeline including CEA-IL2v (RG7813), IDO Inhibitor (GDC-0919) and vanucizumab (anti-Ang2/VEGF, RG7221).